Modality
ERT
MOA
FGFRi
Target
Nectin-4
Pathway
STING
LGS
Development Pipeline
Preclinical
Nov 2017
→ Apr 2028
PreclinicalCurrent
NCT07000897
1,981 pts·LGS
2017-11→2028-04·Terminated
1,981 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-012.0y awayInterim· LGS
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Termina…
Catalysts
Interim
2028-04-01 · 2.0y away
LGS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07000897 | Preclinical | LGS | Terminated | 1981 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| IDY-3466 | Ideaya Bio | NDA/BLA | Nectin-4 | |
| VYG-2970 | Voyager | Phase 3 | JAK1 |